trending Market Intelligence /marketintelligence/en/news-insights/trending/pfjt7smjxtodpzouhg9mdq2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Loxo's thyroid cancer drug granted US FDA breakthrough therapy status

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Loxo's thyroid cancer drug granted US FDA breakthrough therapy status

Loxo Oncology Inc. said the U.S. Food and Drug Administration granted breakthrough therapy designation to its thyroid cancer medicine LOXO-292.

The Stamford, Conn.-based biopharmaceutical company said the FDA status was granted to treat patients with certain tumor mutations whose thyroid cancer worsened following other treatments.

Loxo said the breakthrough therapy designation is the third granted to LOXO-292. The company said the FDA decision was based on data from its ongoing phase 1/2 trial, dubbed Libretto-001, during which the drug has shown efficacy.

The FDA grants breakthrough therapy designation to expedite the development and review of drugs that demonstrate substantial improvement over existing therapies to treat a serious or life-threatening disease or condition.